- Home
- SLP vs ANAB Comparison
SLP vs ANAB Comparison
Compare SLP & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLP
- ANAB
- Stock Information
- Founded
- SLP 1996
- ANAB 2005
- Country
- SLP United States
- ANAB United States
- Employees
- SLP N/A
- ANAB N/A
- Industry
- SLP EDP Services
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- SLP Technology
- ANAB Health Care
- Exchange
- SLP Nasdaq
- ANAB Nasdaq
- Market Cap
- SLP 675.9M
- ANAB 621.1M
- IPO Year
- SLP 1997
- ANAB 2017
- Fundamental
- Price
- SLP $18.32
- ANAB $22.50
- Analyst Decision
- SLP Buy
- ANAB Buy
- Analyst Count
- SLP 7
- ANAB 10
- Target Price
- SLP $40.40
- ANAB $44.25
- AVG Volume (30 Days)
- SLP 571.2K
- ANAB 659.2K
- Earning Date
- SLP 07-14-2025
- ANAB 08-04-2025
- Dividend Yield
- SLP 0.32%
- ANAB N/A
- EPS Growth
- SLP N/A
- ANAB N/A
- EPS
- SLP 0.36
- ANAB N/A
- Revenue
- SLP $78,564,000.00
- ANAB $111,872,000.00
- Revenue This Year
- SLP $27.66
- ANAB N/A
- Revenue Next Year
- SLP $6.75
- ANAB $24.39
- P/E Ratio
- SLP $51.73
- ANAB N/A
- Revenue Growth
- SLP 21.49
- ANAB 387.20
- 52 Week Low
- SLP $16.72
- ANAB $12.21
- 52 Week High
- SLP $49.05
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- SLP 29.54
- ANAB 45.71
- Support Level
- SLP $16.78
- ANAB $22.49
- Resistance Level
- SLP $17.70
- ANAB $24.86
- Average True Range (ATR)
- SLP 1.15
- ANAB 1.15
- MACD
- SLP -0.00
- ANAB -0.27
- Stochastic Oscillator
- SLP 14.61
- ANAB 0.00
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).